The Multiple Sclerosis Network of Care Australia recently compared the outcomes of large population studies by Multiple Sclerosis Research Australia (MSRA) in 2012, the (then) Multiple Society of NSW in 2001 and the Multiple Sclerosis International Federation (MSIF) in 2012, with published research relating to the long term outcomes (2011 to 2015) of successfully treating CCSVI conditions with Angioplasty/Venoplasty. The population studies encompassed 15,184 people with MS who had not had this treatment. This group included 70% of people diagnosed with multiple sclerosis in NSW, 12% across Australia and 10,090 across the globe. The treatment group involved 2150 examinations across 366 CCSVI affected patients independently monitored over a 4 year time span. This comparison showed that the symptoms relieved through the successful PTA treatment of CCSVI irregularities (across all MS sub types) corresponded significantly with the top 20 symptoms identified by these highly regarded population studies. This is significant. It also paves the way for potential comparisons as between the benefits of PTA interventions and the range of non CCSVI treatment options/medications currently recommended for each of these symptoms. See http://www.msnetwork.org/results/ccsvibenefits.htm#Figure_1 Comparisons of this type are important in translating broader based CCSVI knowledge into the “here and now” world of those living with MS. They also complement more rigorous clinical trials on this topic. In this regard an overview of the current state of play is at http://www.msnetwork.org/results Peter Sullivan, MS Network of Care, Australia -- Kerri Cassidy, CEO CCSVI Australia